We describe a 26-year-old man with metastatic choriocarcinoma who presented with hyperthyroidism associated with elevated β-human chorionic gonadotropin (B-HCG) and respiratory failure secondary to diffuse lung metastasis. After the first cycle of chemotherapy, the concentration of B-HCG dramatically decreased and the patient became euthyroid, allowing us to discontinue antithyroid medications. The patient's hyperthyroidism was caused by stimulation of the thyroid gland by high B-HCG levels, as shown by the marked improvement of the patient's thyroid function panel after chemotherapy.
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H uman chorionic gonadotropin (HCG)-induced hyperthyroidism is a rare cause of hyperthyroidism. It is seen in patients suff ering from conditions associated with extremely high levels of HCG, such as hyperemesis gravidarum, hydatidiform moles, and germ cell tumors. At very high levels, HCG can stimulate the TSH receptor, causing hyperthyroidism (1) . We present the case of a 26-year-old man diagnosed with metastatic choriocarcinoma and concomitant hyperthyroidism related to extremely high levels of β-human chorionic gonadotropin (B-HCG). Th e patient's hyperthyroidism resolved as the B-HCG decreased because of chemotherapy.
CASE DESCRIPTION
A previously healthy 26-year-old man presented with a 3-week history of fever, chills, cough, hemoptysis, and dyspnea. He also reported anxiety, palpitations, hand tremors, and a 30-pound weight loss in a 3-month period. A chest radiograph showed multiple diff use nodules of 1 to 3.5 cm throughout both lung fi elds (Figure 1) . Upon presentation at our hospital, his heart rate was 136 beats per minute, and his respiratory rate was 25 breaths per minute. On initial exam he had fi ne crackles in both lung bases. Th e thyroid gland and scrotal examinations were unremarkable. His free thyroxine was 4.14 ng/dL (normal, 0.93-1.7); free triiodothyronine, 10.6 pg/mL (normal, 2. Testicular ultrasound showed a heterogeneous right testicle with microlithiasis and a 10 mm septated upper pole cyst, with moderate right hydrocele. Computed tomography (CT) of the head, chest (Figure 2) , abdomen, and pelvis suggested diff use metastasis of the brain, lungs, liver, and retroperitoneal lymph nodes. CT-guided biopsy of one of the lung nodules was consistent with metastatic choriocarcinoma based on positive staining for B-HCG.
Th e patient was treated with bleomycin, etoposide, and cisplatin. After completing his fi rst chemotherapy cycle, his serum B-HCG decreased signifi cantly and the thyroid function panel improved to near normalization (Table 1 ). Methimazole was decreased from 45 mg to 10 mg daily and was discontinued 3 weeks after he completed the fi rst cycle of chemotherapy. At discharge,
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DISCUSSION
HCG is a glycoprotein hormone that has intrinsic thyroidstimulating activity (2) . HCG-alpha subunit is common to all the glycoprotein hormones (follicle-stimulating hormone, luteinizing hormone, TSH). HCG and TSH-beta subunit are highly homologous (3): both contain 12 half-cysteine residues and one N-linked oligosaccharide, and three disulphide bonds from a cysteine knot structure are identical in both hormones and essential for binding to the receptor (4). HCG is, therefore, able to cross-react with the TSH receptor (5) and can induce hyperthyroidism when the HCG levels are high enough (3).
Testicular tumors account for 1% of male malignancies in the USA, and more than 95% originate from germ cells that are classifi ed as seminomatous or nonseminomatous germ cell tumors (NSGCT) (6) . NSGCT can secrete HCG, and some patients can develop hyperthyroidism as a paraneoplastic phenomenon (1) . Th e prevalence of hyperthyroidism in patients with NSGCT presenting with elevated levels of HCG is not known, although in a large cohort of 144 patients with NSGCT, hyperthyroidism was found in 5 patients (3.5%) with HCG levels >50,000 mIU/mL. Th e prevalence of hyperthyroidism in those with serum HCG >50,000 mIU/mL was 50% (1). In another series of 17 patients with NSGCT, hyperthyroidism was reported in 7 patients (41%) with HCG >50,000 mIU/mL. Th e fact that some patients, but not all with very high levels of HCG, present with hyperthyroidism is thought to be due to secondary modifi cations of HCG such as sialylation or glycosylation that can aff ect HCG bioactivity and the sensitivity of the TSH receptor to HCG (5). Haddow et al reported that in a series of 9562 pregnant women, TSH was substantially suppressed when the ratio of HCG to TSH was >200,000. In another series, Lockwood et al collected 69 serum samples with HCG > 200,000 IU/L and found a suppressed TSH in 100% of specimens with HCG concentrations >400,000 IU/L (7). In general, it is accepted that 25,000 U/L of HCG is roughly equivalent to 1 mU/L of TSH activity (3), and although there is not a precise threshold at which HCG causes hyperthyroidism, thyroid functions should be measured in all patients with HCG >50,000 IU/L, regardless of the cause of HCG excess (1, 8) .
Th e primary treatment for paraneoplastic HCG secretion consists of NSGCT-directed chemotherapy along with symptomatic treatment of hyperthyroidism. Chemotherapy may produce an initial HCG surge, and patients should be monitored for signs of thyrotoxicosis or thyroid storm, but it is usually followed by normalization of thyroid function if the underlying disease is responsive to treatment (1, 3). 
